- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
Latuda
Synonyms :
Class :
Atypical antipsychotics
Dosage Forms & Strengths
Tablet
20mg
40mg
60mg
80mg
120mg
Dosage Forms & Strengths
Tablet
20mg
40mg
60mg
80mg
120mg
Refer adult dosing
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
when both drugs are combined, there may be an increased effect of lurasidone by affecting hepatic or intestinal enzyme cyp3a4 metabolism
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism
the effect of lurasidone is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
CYP3A strong enhancers of the small intestine may reduce the bioavailability of lurasidone
it decreases the effects of antipsychotic agents
antihypertensive agents increase the efficacy of antipsychotic agents
antihypertensive agents increase the efficacy of antipsychotic agents
antihypertensive agents increase the efficacy of antipsychotic agents
antihypertensive agents increase the efficacy of antipsychotic agents
antihypertensive agents increase the efficacy of antipsychotic agents
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
it may increase the neurotoxic effect of antipsychotic agents
It may increase the neurotoxic effect of Antipsychotic Agents
It may increase the neurotoxic effect of Antipsychotic Agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
It may increase the neurotoxic effect of Antipsychotic Agents
it may increase the risk of adverse effects of antipsychotic agents
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
Serotonergic Agents may enhance the adverse/toxic effect of antipsychotic Agents
serotonergic Agents may enhance the adverse/toxic effect of antipsychotic Agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may increase the hypotensive effect of anti-hypertensives
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the hypotensive effect of antipsychotic agents
may enhance the hypotensive effect of antipsychotic agents
may enhance the hypotensive effect of antipsychotic agents
may enhance the hypotensive effect of antipsychotic agents
may enhance the hypotensive effect of antipsychotic agents
may increase the hypotensive effect of blood pressure-lowering agents
may enhance the bradycardic effect of beta blockers
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the hypotensive effect of blood pressure-lowering agents
may increase the risk of adverse effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may increase the neurotoxic (central) effect
may increase the neurotoxic (central) effect
may increase the neurotoxic (central) effect
may increase the neurotoxic (central) effect
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
antipsychotic agents increase the arrhythmogenic effect of mequitazine in the serum
Adverse drug reactions:
>10%
Nausea (9-13%)
Insomnia (7-11%)
Extrapyramidal disorder (6-22%)
Parkinsonism (6-17%)
Somnolence (15-26%)
Akathisia (6-22%)
Fasting glucose increased (10-14%)
1-10%
Vomiting (6-8%)
Agitation (3-10%)
Anxiety (3-8%)
Dyspepsia (5-8%)
Back pain (2-4%)
Restlessness (3%)
Hypertension
Rash
Dizziness (4-6%)
Fatigue (4%)
Elevated serum creatinine (1-7.2%)
Dystonia (5%)
Pruritus
CPK increased
Pregnancy warnings:
AU TGA pregnancy category: B1
US FDA pregnancy category: N/A
Lactation:
Excreted into human milk is UNknown
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category